^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + gemcitabine (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
Excerpt:
Cisplatin–gemcitabine is recommended as SoC in the first-line setting for patients with a PS of 0-1 [I, A].
